Terms: = Ovarian cancer AND ETV1, DKFZp781L0674, 2115, ENSG00000006468, ER81, MGC120533, MGC104699, MGC120534 AND Clinical Outcome
1 results:
1. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.
Roque DM; Buza N; Glasgow M; Bellone S; Bortolomai I; Gasparrini S; Cocco E; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
Clin Exp Metastasis; 2014 Jan; 31(1):101-10. PubMed ID: 24005572
[TBL] [Abstract] [Full Text] [Related]
